NICE says 'no' to Pfizer's Vyndaqel for rare heart condition

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decid

Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’